HRMY — Harmony Biosciences Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapContrarian

Annual income statement for Harmony Biosciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	305	438	582	715	868
Cost of Revenue
Gross Profit	250	354	461	558	670
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	244	318	400	524	660
Operating Profit	61.4	120	182	191	208
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	37.4	105	173	192	215
Provision for Income Taxes
Net Income After Taxes	34.6	181	129	145	159
Net Income Before Extraordinary Items
Net Income	34.6	181	129	145	159
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	34.6	181	129	145	159
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.993	2.97	2.25	2.51	2.71